Benzinga | Oct 15, 2020 07:31AM EDT

Armata Pharmaceuticals Announces Clearance Of Investigational New Drug Application To Initiate Phase 1b/2a Clinical Trial Of Lead Candidate AP-PA02 In Pseudomonas Aeruginosa Infections

Upcoming study, to be known as "SWARM-P.a.," is believed to be first FDA cleared, controlled clinical trial to evaluate a multiple phage-based mixture as a therapeutic candidate in Cystic Fibrosis patients

MARINA DEL REY, Calif., Oct. 15, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (FDA) has cleared Armata's IND to initiate a clinical trial of its lead therapeutic candidate, AP-PA02, in Pseudomonas aeruginosa infections.